Arbutus Biopharma Corp (ABUS) to Post Q1 2017 Earnings of ($0.38) Per Share, Leerink Swann Forecasts

Arbutus Biopharma Corp (NASDAQ:ABUS) – Leerink Swann issued their Q1 2017 earnings per share (EPS) estimates for shares of Arbutus Biopharma Corp in a note issued to investors on Wednesday, Zacks Investment Research reports. Leerink Swann analyst M. Schmidt expects that the biopharmaceutical company will post earnings per share of ($0.38) for the quarter. Leerink Swann also issued estimates for Arbutus Biopharma Corp’s Q2 2017 earnings at ($0.40) EPS.

A number of other brokerages have also recently issued reports on ABUS. Zacks Investment Research upgraded Arbutus Biopharma Corp from a “sell” rating to a “hold” rating in a report on Friday, February 17th. Wedbush reiterated an “outperform” rating and set a $10.00 price target (up previously from $9.00) on shares of Arbutus Biopharma Corp in a report on Wednesday, March 22nd. Bloom Burton upgraded Arbutus Biopharma Corp from an “accumulate” rating to a “buy” rating in a report on Monday, January 9th. Finally, Chardan Capital upgraded Arbutus Biopharma Corp from a “neutral” rating to a “buy” rating and lifted their price target for the company from $3.00 to $6.00 in a report on Tuesday, April 4th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Arbutus Biopharma Corp has a consensus rating of “Buy” and an average price target of $6.25.

Earnings History and Estimates for Arbutus Biopharma Corp (NASDAQ:ABUS)

ILLEGAL ACTIVITY NOTICE: “Arbutus Biopharma Corp (ABUS) to Post Q1 2017 Earnings of ($0.38) Per Share, Leerink Swann Forecasts” was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2017/04/20/analysts-offer-predictions-for-arbutus-biopharma-corps-q1-2017-earnings-abus-updated-updated.html.

Arbutus Biopharma Corp (NASDAQ:ABUS) traded up 0.758% during mid-day trading on Thursday, reaching $3.325. The company’s stock had a trading volume of 211,353 shares. Arbutus Biopharma Corp has a 1-year low of $2.35 and a 1-year high of $5.48. The firm has a 50 day moving average price of $3.08 and a 200-day moving average price of $2.88. The company’s market capitalization is $182.95 million.

Hedge funds have recently added to or reduced their stakes in the stock. Ladenburg Thalmann Financial Services Inc. boosted its stake in Arbutus Biopharma Corp by 1,058,889.0% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 5,294,945 shares of the biopharmaceutical company’s stock worth $12,972,000 after buying an additional 5,294,445 shares during the last quarter. Armistice Capital LLC boosted its stake in Arbutus Biopharma Corp by 38.6% in the fourth quarter. Armistice Capital LLC now owns 1,940,000 shares of the biopharmaceutical company’s stock worth $4,753,000 after buying an additional 540,000 shares during the last quarter. Bank of Montreal Can boosted its stake in Arbutus Biopharma Corp by 6.3% in the third quarter. Bank of Montreal Can now owns 861,553 shares of the biopharmaceutical company’s stock worth $2,964,000 after buying an additional 50,768 shares during the last quarter. Baker BROS. Advisors LP purchased a new stake in Arbutus Biopharma Corp during the third quarter worth about $621,000. Finally, Oxford Asset Management purchased a new stake in Arbutus Biopharma Corp during the fourth quarter worth about $392,000. 61.24% of the stock is owned by hedge funds and other institutional investors.

About Arbutus Biopharma Corp

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

5 Day Chart for NASDAQ:ABUS

Get a free copy of the Zacks research report on Arbutus Biopharma Corp (ABUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Arbutus Biopharma Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply